Q-omics provides the consensus-scored BCRP4 profile across patient tissues and cancer cell-line models. BCRP4 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, BCRP4 is differentially expressed in 2, with the highest sampling consensus in KICH. Additionally, BCRP4 RNA expression shows 6,389 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight READ, KICH, and STAD as cancer lineages where BCRP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCRP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCRP4 survival associations across molecular data types. BCRP4 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCRP4 RNA expression–survival associations across cancer types. High BCRP4 expression shows unfavorable associations in READ, TGCT, SKCM, THCA and PAAD, but favorable associations in STAD. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for BCRP4 RNA expression.
This table summarizes BCRP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for BCRP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCRP4 shows lower tumor expression in KICH and higher tumor expression in COAD. The KICH box plot shows higher BCRP4 RNA expression in normal versus tumor tissue (log2 FC = −0.128, t-test p < 0.001).
This table shows molecular features associated with BCRP4 in patient tissues and cancer cell lines. In patient samples, BCRP4 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
